Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

80.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 80.50
Bid (Size) 32.20 (2)
Ask (Size) 87.08 (2)
Prev. Close 80.50
Today's Range 80.50 - 80.50
52wk Range 76.02 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
The 3 Best Biotech Stocks to Buy in May 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace

Performance

YTD
-17.90%
-17.90%
1 Month
-12.03%
-12.03%
3 Month
-8.71%
-8.71%
6 Month
-3.47%
-3.47%
1 Year
-15.42%
-15.42%

More News

Read More
Citi Just Cut Its Price Target on These 3 Stocks
Via InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable.
Via Chartmill
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
3 No-Brainer Stocks to Buy With $200 Right Now
Via The Motley Fool
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Via InvestorPlace
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.